Punjab authorities have imposed an immediate ban on the sale and distribution of the cough syrup brand ‘Coldrif’ after laboratory findings connected the product to the deaths of 16 children in Madhya Pradesh. The decision follows alarming test results that detected dangerously high levels of diethylene glycol, a chemical commonly used in industrial applications but highly toxic when ingested by humans.

Public Health Alert Over Contaminated Medicine

The state’s health department issued a directive ordering all pharmacies, distributors, and healthcare professionals to stop selling or prescribing Coldrif with immediate effect. Officials emphasized that the move was necessary to protect public health and prevent further harm. The department also urged citizens to check their medicine cabinets and discontinue use of any remaining bottles of the product.

Laboratory Tests Reveal Toxic Substance

According to laboratory analyses, samples of Coldrif contained an excessive concentration of diethylene glycol, a substance sometimes used as a solvent or antifreeze component. Even small amounts of this compound can cause severe kidney and liver damage, neurological complications, or death if consumed. The discovery prompted swift action from authorities across multiple states to trace and remove affected batches from circulation.

Connection to Deaths in Madhya Pradesh

The ban was implemented after reports emerged from Madhya Pradesh linking the deaths of 16 children to consumption of the same cough syrup brand. Medical investigations suggested that the toxic contamination was responsible for the fatalities, leading neighboring states like Punjab to take preventive measures. Health officials stated that they are coordinating with central agencies to ensure no contaminated stock remains available in markets or medical facilities.

Retailers and Practitioners Ordered to Comply

In its notification, Punjab’s health department instructed all chemists and medical practitioners to immediately withdraw Coldrif from shelves and refrain from prescribing it under any circumstances. Inspections have been initiated across districts to verify compliance, with strict penalties expected for violations. Authorities also appealed for cooperation from healthcare workers in identifying any patients who may have recently used the product so they can receive prompt medical evaluation if needed.

Broader Concerns About Drug Safety

This incident has reignited discussion about pharmaceutical quality control and regulatory oversight within India’s drug manufacturing sector. Experts note that contamination with industrial chemicals like diethylene glycol has been linked to several past tragedies worldwide, underscoring the importance of rigorous testing standards and transparent supply chains. Public health advocates are calling for stronger enforcement mechanisms to prevent similar occurrences in the future.

The Punjab government’s swift response highlights growing vigilance toward medicine safety following reports from Madhya Pradesh. As investigations continue, authorities are urging consumers to remain cautious about over-the-counter medications and report any adverse reactions immediately. The ban on Coldrif is expected to remain in place until further notice while officials assess long-term safety measures for pharmaceutical products distributed within the state.